Keio Innovation Initiative (KII) has made an additional investment in Metagen Therapeutics, a company promoting microbiome drug discovery, from a fund managed by KII. Metagen Therapeutics will use the funds raised this time to promote the construction of a “gut microbiota bank” to connect patients who need gut microbiota and donors who provide gut microbiota in order to promote gut microbiota transplantation medicine (FMT) in actual clinical practice. In addition, the company will expand its business to reverse translational drug discovery using the intestinal microbiota whose safety and efficacy have been confirmed in advance by FMT, starting from FMT.

For more details, please see the press release.
https://prtimes.jp/main/html/rd/p/000000042.000018580.html